| Code | CSB-RA004848MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to AZD7798, targeting CCR9 (C-C chemokine receptor type 9), a G protein-coupled receptor primarily expressed on lymphocytes in the gut-associated lymphoid tissue. CCR9 mediates lymphocyte homing to the small intestine through interaction with its ligand CCL25, playing a crucial role in mucosal immunity and intestinal inflammation. Dysregulation of the CCR9/CCL25 axis has been implicated in inflammatory bowel diseases, particularly Crohn's disease, as well as in certain hematological malignancies including T-cell acute lymphoblastic leukemia where aberrant CCR9 expression promotes disease progression.
AZD7798 was originally developed as a therapeutic monoclonal antibody designed to block CCR9-mediated lymphocyte trafficking to inflamed intestinal tissue. This biosimilar provides researchers with a valuable tool for investigating CCR9-dependent mechanisms in gastrointestinal immunology, inflammatory disease models, and cancer biology. The antibody enables studies of lymphocyte migration, mucosal immune responses, and the therapeutic potential of CCR9 antagonism in various disease contexts.
There are currently no reviews for this product.